Roche Holding AG (ROGN MX) stock market data APIs
₱7217.456
0(0%)
as of January 2, 2026
Try our APIs with
free plan!
Roche Holding AG Financial Data Overview
Price chart is built with
Anychart
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Prev. Close
7217.456
Open
7217.456
High
7217.456
Low
7217.456
52 wk Range
5002-7278.3198
Market Cap
5 741 781 M
P/E Ratio
27.0266
Shares Outstanding
690 M
Revenue
63 488 M
Dividends (Yield)
0.0013
Beta
0.171
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Roche Holding AG data using free add-ons & libraries
Get Roche Holding AG Fundamental Data
Roche Holding AG Fundamental data includes:
- Net Revenue: 63 488 M
- EBITDA: 23 429 M
- Earnings Per Share: 266
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG News
New
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
Corcept Therapeutics CORT announced that the FDA has issued a complete response letter (“CRL”) to its new drug application (“NDA”), seeking approval for its proprietary, selective cortisol mod...
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have surged 41% in this time frame, outpacing the industry’s growth of 22.4%. The ...
Frédéric Prince to Succeed Christian Loss, Effective January 1st, 2026
RAPPERSWIL, Switzerland, January 02, 2026--(BUSINESS WIRE)--Dr. Christian Loss, Chief Executive Officer (CEO) of Neovii Pharmaceuticals AG, will take a well-deserved retirement after his distinguished...
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Royalty Pharma plc Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020 NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma pl...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
